# Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

> **NCT03228537** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (actual)

## Conditions studied

- Biphasic Mesothelioma
- Epithelioid Mesothelioma
- Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7
- Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
- Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7
- Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7
- Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Cisplatin
- **PROCEDURE:** Extrapleural Pneumonectomy
- **DRUG:** Pemetrexed Disodium
- **PROCEDURE:** Pleurectomy
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03228537
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-16
- **Primary completion:** 2022-10-01
- **Final completion:** 2026-09-18
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03228537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03228537, "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03228537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*